Abiomed Inc. (ABMD): Price and Financial Metrics
ABMD Price/Volume Stats
| Current price | $381.02 | 52-week high | $381.99 |
| Prev. close | $380.79 | 52-week low | $219.85 |
| Day low | $380.51 | Volume | 20,612,200 |
| Day high | $381.28 | Avg. volume | 611,028 |
| 50-day MA | $343.62 | Dividend yield | N/A |
| 200-day MA | $291.25 | Market Cap | 17.18B |
ABMD Stock Price Chart Interactive Chart >
Abiomed Inc. (ABMD) Company Bio
Abiomed is a publicly-traded medical device technology company that develops and manufactures temporary external and implantable mechanical circulatory support devices. The company is headquartered in Danvers, Massachusetts with additional offices in Woburn, Baltimore, Berlin, Aachen, and Tokyo. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer and Dr. Chuck Simonton as Chief Medical Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2022, the company had secured five FDA approvals and 1,408 patents with 1,416 pending. For fiscal year 2022, Abiomed reported $1.032 billion in revenue and reported diluted earnings per share was $2.98 for the year. (Source:Wikipedia)
Latest ABMD News From Around the Web
Below are the latest news stories about ABIOMED INC that investors may wish to consider to help them evaluate ABMD as an investment opportunity.
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical TrialDANVERS, Mass., December 21, 2022--Abiomed Announces First Patients Enrolled in FDA Pivotal Trial for Impella ECP, World’s Smallest Heart Pump |
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions. |
10 Best Performing Stocks in NovemberIn this article, we discuss the 10 best performing stocks in November. If you want to read about some more best performing stocks in November, go directly to 5 Best Performing Stocks in November. After the eventful month of October, which is widely known for stock market crashes, the United States (US) stock market jumped […] |
The 3 Best Funds to Buy for a Roth IRALooking to start an after-tax-funded individual retirement account? |
Abiomed stock ticks higher after HSR waiting period for J&J sale expiresAbiomed (ABMD) ticked up 1% in premarket trading after the antitrust waiting period for its sale to Johnson & Johnson (JNJ) expired.The required waiting period under the HSR act expired… |
ABMD Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 7.78% |
| 5-year | 104.40% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | 10.79% |
| 2020 | 90.05% |
| 2019 | -47.52% |
Continue Researching ABMD
Here are a few links from around the web to help you further your research on Abiomed Inc's stock as an investment opportunity:Abiomed Inc (ABMD) Stock Price | Nasdaq
Abiomed Inc (ABMD) Stock Quote, History and News - Yahoo Finance
Abiomed Inc (ABMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...